Why gene-therapy drugs are so expensive
By N.L.,
The Economist
| 08. 03. 2016
Untitled Document
On August 3rd the British pharmaceutical company GSK said that it would charge €594,000 ($665,000) for a gene-therapy cure for ADA-SCID—a severe immune disorder that is usually fatal in the first few years of life. A child born with ADA-SCID is unable to fight off everyday infections; Strimvelis has cured this in each of the 18 children it has been tested on over 15 years. Gene therapies work by delivering correct versions of DNA, usually using a virus as a vector. Once DNA is inside the cell, it produces the protein that was missing and the fault is fixed. Scientists have been trying to develop gene therapies for decades. Early work hit the buffers due to a series of unexpected cancers, the death of a young man during a trial, and some disappointing results.
Much progress has been made since then and according to analysts at Datamonitor Healthcare the number of gene therapies in development has doubled since 2012. Last week, America’s Food and Drug Administration (FDA) handed out “breakthrough” designations—intended to hasten the approval of important new...
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...
